| Year |
Citation |
Score |
| 2024 |
Rickelton K, Zintel TM, Pizzollo J, Miller E, Ely JJ, Raghanti MA, Hopkins WD, Hof PR, Sherwood CC, Bauernfeind AL, Babbitt CC. Tempo and mode of gene expression evolution in the brain across primates. Elife. 13. PMID 38275218 DOI: 10.7554/eLife.70276 |
0.52 |
|
| 2015 |
Bauernfeind AL, Soderblom EJ, Turner ME, Moseley MA, Ely JJ, Hof PR, Sherwood CC, Wray GA, Babbitt CC. Evolutionary divergence of gene and protein expression in the brains of humans and chimpanzees. Genome Biology and Evolution. PMID 26163674 DOI: 10.1093/Gbe/Evv132 |
0.607 |
|
| 2015 |
Bauernfeind AL, Reyzer ML, Caprioli RM, Ely JJ, Babbitt CC, Wray GA, Hof PR, Sherwood CC. High spatial resolution proteomic comparison of the brain in humans and chimpanzees. The Journal of Comparative Neurology. PMID 25779868 DOI: 10.1002/Cne.23777 |
0.627 |
|
| 2014 |
Bauernfeind AL, Babbitt CC. The appropriation of glucose through primate neurodevelopment. Journal of Human Evolution. 77: 132-40. PMID 25110208 DOI: 10.1016/j.jhevol.2014.05.016 |
0.311 |
|
| 2014 |
Bauernfeind AL, Barks SK, Duka T, Grossman LI, Hof PR, Sherwood CC. Aerobic glycolysis in the primate brain: reconsidering the implications for growth and maintenance. Brain Structure & Function. 219: 1149-67. PMID 24185460 DOI: 10.1007/S00429-013-0662-Z |
0.652 |
|
| 2014 |
Barks SK, Bauernfeind AL, Bonar CJ, Cranfield MR, de Sousa AA, Erwin JM, Hopkins WD, Lewandowski AH, Mudakikwa A, Phillips KA, Raghanti MA, Stimpson CD, Hof PR, Zilles K, Sherwood CC. Variable temporoinsular cortex neuroanatomy in primates suggests a bottleneck effect in eastern gorillas. The Journal of Comparative Neurology. 522: 844-60. PMID 23939630 DOI: 10.1002/Cne.23448 |
0.634 |
|
| 2013 |
Bianchi S, Stimpson CD, Duka T, Larsen MD, Janssen WG, Collins Z, Bauernfeind AL, Schapiro SJ, Baze WB, McArthur MJ, Hopkins WD, Wildman DE, Lipovich L, Kuzawa CW, Jacobs B, et al. Synaptogenesis and development of pyramidal neuron dendritic morphology in the chimpanzee neocortex resembles humans. Proceedings of the National Academy of Sciences of the United States of America. 110: 10395-401. PMID 23754422 DOI: 10.1073/Pnas.1301224110 |
0.652 |
|
| 2013 |
Bauernfeind AL, de Sousa AA, Avasthi T, Dobson SD, Raghanti MA, Lewandowski AH, Zilles K, Semendeferi K, Allman JM, Craig AD, Hof PR, Sherwood CC. A volumetric comparison of the insular cortex and its subregions in primates. Journal of Human Evolution. 64: 263-79. PMID 23466178 DOI: 10.1016/J.Jhevol.2012.12.003 |
0.73 |
|
| 2013 |
Bianchi S, Stimpson CD, Bauernfeind AL, Schapiro SJ, Baze WB, McArthur MJ, Bronson E, Hopkins WD, Semendeferi K, Jacobs B, Hof PR, Sherwood CC. Dendritic morphology of pyramidal neurons in the chimpanzee neocortex: regional specializations and comparison to humans. Cerebral Cortex (New York, N.Y. : 1991). 23: 2429-36. PMID 22875862 DOI: 10.1093/Cercor/Bhs239 |
0.662 |
|
| 2012 |
Sherwood CC, Bauernfeind AL, Bianchi S, Raghanti MA, Hof PR. Human brain evolution writ large and small. Progress in Brain Research. 195: 237-54. PMID 22230630 DOI: 10.1016/B978-0-444-53860-4.00011-8 |
0.62 |
|
| 2011 |
Bianchi S, Bauernfeind AL, Gupta K, Stimpson CD, Spocter MA, Bonar CJ, Manger PR, Hof PR, Jacobs B, Sherwood CC. Neocortical neuron morphology in Afrotheria: comparing the rock hyrax with the African elephant. Annals of the New York Academy of Sciences. 1225: 37-46. PMID 21534991 DOI: 10.1111/J.1749-6632.2011.05991.X |
0.705 |
|
| 2010 |
Spocter MA, Hopkins WD, Garrison AR, Bauernfeind AL, Stimpson CD, Hof PR, Sherwood CC. Wernicke's area homologue in chimpanzees (Pan troglodytes) and its relation to the appearance of modern human language. Proceedings. Biological Sciences / the Royal Society. 277: 2165-74. PMID 20236975 DOI: 10.1098/Rspb.2010.0011 |
0.719 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2019 |
Bauernfeind AL, Babbitt CC. Genetic diversity underlying behavioral plasticity in human adaptation. Progress in Brain Research. 250: 41-58. PMID 31703908 DOI: 10.1016/bs.pbr.2019.06.002 |
0.294 |
|
| 2020 |
Bauernfeind AL, Babbitt CC. Metabolic changes in human brain evolution. Evolutionary Anthropology. PMID 32329960 DOI: 10.1002/evan.21831 |
0.283 |
|
| 2008 |
Riccardi P, Baldwin R, Salomon R, Anderson S, Ansari MS, Li R, Dawant B, Bauernfeind A, Schmidt D, Kessler R. Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride. Biological Psychiatry. 63: 241-4. PMID 17586476 DOI: 10.1016/J.Biopsych.2007.03.022 |
0.24 |
|
| 2011 |
Bauernfeind AL, Dietrich MS, Blackford JU, Charboneau EJ, Lillevig JG, Cannistraci CJ, Woodward ND, Cao A, Watkins T, Di Iorio CR, Cascio C, Salomon RM, Cowan RL. Human Ecstasy use is associated with increased cortical excitability: an fMRI study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 1127-41. PMID 21326196 DOI: 10.1038/Npp.2010.244 |
0.234 |
|
| 2022 |
Maloney SE, Tabachnick DR, Jakes C, Avdagic S, Bauernfeind AL, Dougherty JD. Fluoxetine exposure throughout neurodevelopment differentially influences basilar dendritic morphology in the motor and prefrontal cortices. Scientific Reports. 12: 7605. PMID 35534532 DOI: 10.1038/s41598-022-11614-w |
0.207 |
|
| 2017 |
Bauernfeind AL, Babbitt CC. The predictive nature of transcript expression levels on protein expression in adult human brain. Bmc Genomics. 18: 322. PMID 28438116 DOI: 10.1186/s12864-017-3674-x |
0.168 |
|
| 2011 |
Salomon RM, Cowan RL, Rogers BP, Dietrich MS, Bauernfeind AL, Kessler RM, Gore JC. Time series fMRI measures detect changes in pontine raphé following acute tryptophan depletion. Psychiatry Research. 191: 112-21. PMID 21236648 DOI: 10.1016/j.pscychresns.2010.10.007 |
0.151 |
|
| 2010 |
Raj V, Liang HC, Woodward ND, Bauernfeind AL, Lee J, Dietrich MS, Park S, Cowan RL. MDMA (ecstasy) use is associated with reduced BOLD signal change during semantic recognition in abstinent human polydrug users: a preliminary fMRI study. Journal of Psychopharmacology (Oxford, England). 24: 187-201. PMID 19304866 DOI: 10.1177/0269881109103203 |
0.146 |
|
| 2015 |
Schneider I, Bauernfeind A. Intrinsic Carbapenem-Hydrolyzing Oxacillinases from Members of the Genus Pandoraea. Antimicrobial Agents and Chemotherapy. 59: 7136-41. PMID 26349828 DOI: 10.1128/AAC.01112-15 |
0.117 |
|
| 1998 |
Bauernfeind A, Schneider I, Jungwirth R, Roller C. Discrimination of Burkholderia gladioli from other Burkholderia species detectable in cystic fibrosis patients by PCR. Journal of Clinical Microbiology. 36: 2748-51. PMID 9705429 |
0.098 |
|
| 1993 |
Bauernfeind A. In-vitro activity of dirithromycin in comparison with other new and established macrolides. The Journal of Antimicrobial Chemotherapy. 31: 39-49. PMID 8478311 |
0.091 |
|
| 2008 |
Schneider I, Keuleyan E, Rasshofer R, Markovska R, Queenan AM, Bauernfeind A. VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. Antimicrobial Agents and Chemotherapy. 52: 2977-9. PMID 18519714 DOI: 10.1128/Aac.00175-08 |
0.088 |
|
| 1998 |
Bauernfeind A, Hohl P, Schneider I, Jungwirth R, Frei R. Escherichia coli producing a cephamycinase (CMY-2) from a patient from the Libyan---Tunisian border region. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 4: 168-170. PMID 11864315 |
0.086 |
|
| 1998 |
Bauernfeind A, Hohl P, Schneider I, Jungwirth R, Frei R. Escherichia coli producing a cephamycinase (CMY-2) from a patient from the Libyan-Tunisian border region Clinical Microbiology and Infection. 4: 168-170. |
0.086 |
|
| 2001 |
Bauernfeind A. ["So rich and yet so poor!"]. ã–Sterreichische Pflegezeitschrift : Organ Des ã–Sterreichischen Gesundheits- Und Krankenpflegeverbands. 54: 22-3. PMID 11942272 |
0.078 |
|
| 1986 |
Bauernfeind A, Hörl G, Mönch V. Changes in microbial ecology by therapeutic use of aminoglycosides Scandinavian Journal of Infectious Diseases, Supplement. 49: 106-114. PMID 3547617 |
0.073 |
|
| 1990 |
Theopold M, Benner U, Bauernfeind A. [Effectiveness and tolerance of cefixime in bacterial infections in the ENT area]. Infection. 18: S122-4. PMID 2079370 DOI: 10.1007/BF01644629 |
0.072 |
|
| 1991 |
Goussard S, Sougakoff W, Mabilat C, Bauernfeind A, Courvalin P. An IS1-like element is responsible for high-level synthesis of extended-spectrum beta-lactamase TEM-6 in Enterobacteriaceae. Journal of General Microbiology. 137: 2681-7. PMID 1665171 DOI: 10.1099/00221287-137-12-2681 |
0.072 |
|
| 1991 |
Bauernfeind A. Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany. Diagnostic Microbiology and Infectious Disease. 14: 63-74. PMID 2013211 DOI: 10.1016/0732-8893(91)90091-S |
0.071 |
|
| 2006 |
Schneider I, Queenan AM, Bauernfeind A. Novel carbapenem-hydrolyzing oxacillinase OXA-62 from Pandoraea pnomenusa. Antimicrobial Agents and Chemotherapy. 50: 1330-5. PMID 16569848 DOI: 10.1128/Aac.50.4.1330-1335.2006 |
0.071 |
|
| 1989 |
Bauernfeind A, Jungwirth R, Schweighart S. In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany. The Journal of Antimicrobial Chemotherapy. 24: 73-84. PMID 2509418 |
0.07 |
|
| 2007 |
Damjanova I, Tóth A, Pászti J, Jakab M, Milch H, Bauernfeind A, Füzi M. Epidemiology of SHV-type beta-lactamase-producing Klebsiella spp. from outbreaks in five geographically distant Hungarian neonatal intensive care units: widespread dissemination of epidemic R-plasmids. International Journal of Antimicrobial Agents. 29: 665-71. PMID 17369027 DOI: 10.1016/J.Ijantimicag.2006.12.020 |
0.067 |
|
| 1989 |
Wiedemann B, Adam D, Bauernfeind A, Blasius C, Braveny I, Daschner F, Grimm H, Gärtner, Hahn H, Langmaack H, Ley F, Opferkuch W, Peters G, Rohr HP, Ruckdeschel G, et al. In vitro activity of enoxacin: a multi-center-study | In vitro-Aktivität von Enoxacin: Eine multizentrische Studie Infection. 17: S3-S5. PMID 2509373 DOI: 10.1007/BF01643625 |
0.066 |
|
| 1990 |
Goering RV, Bauernfeind A, Lenz W, Przyklenk B. Staphylococcus aureus in patients with cystic fibrosis: an epidemiological analysis using a combination of traditional and molecular methods. Infection. 18: 57-60. PMID 1968892 DOI: 10.1007/BF01644187 |
0.061 |
|
| 1991 |
Bauernfeind A, Jungwirth R. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil. Infection. 19: 353-62. PMID 1800377 DOI: 10.1007/BF01645369 |
0.058 |
|
| 1997 |
Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. The Journal of Antimicrobial Chemotherapy. 40: 639-51. PMID 9421311 |
0.058 |
|
| 2011 |
Luque Fernández MÁ, Mason PR, Gray H, Bauernfeind A, Fesselet JF, Maes P. Descriptive spatial analysis of the cholera epidemic 2008-2009 in Harare, Zimbabwe: a secondary data analysis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 105: 38-45. PMID 21075411 DOI: 10.1016/j.trstmh.2010.10.001 |
0.058 |
|
| 1990 |
Bauernfeind A, Grimm H, Schweighart S. A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection. 18: 294-8. PMID 2276823 DOI: 10.1007/BF01647010 |
0.056 |
|
| 1991 |
Bauernfeind A. Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases. Diagnostic Microbiology and Infectious Disease. 14: 89-92. PMID 2013215 DOI: 10.1016/0732-8893(91)90095-W |
0.055 |
|
| 1996 |
Schito GC, Acar JF, Bauernfeind A, Duval J, Finch RG, Focht J, Nicoletti G, Phillips I, Pratts G, Soriano F, Wiedeman B, Wise R. A multinational European survey on the in-vitro activity of rufloxacin and other comparative antibiotics on respiratory and urinary bacterial pathogens. The Journal of Antimicrobial Chemotherapy. 38: 627-39. PMID 8937958 |
0.055 |
|
| 1987 |
Bauernfeind A, Hörl G, Przyklenk B. Microbiological perspectives of Co-trimoxazole Infection. 15: S232-S235. PMID 3325434 DOI: 10.1007/BF01643195 |
0.052 |
|
| 2003 |
Yong D, Shin JH, Kim S, Lim Y, Yum JH, Lee K, Chong Y, Bauernfeind A. High prevalence of PER-1 extended-spectrum beta-lactamase-producing Acinetobacter spp. in Korea. Antimicrobial Agents and Chemotherapy. 47: 1749-51. PMID 12709353 DOI: 10.1128/AAC.47.5.1749-1751.2003 |
0.048 |
|
| 1992 |
Bauernfeind A. Bactericidal activity of antibiotics alone and in combination against Enterococcus faecalis in a pharmacodynamic model. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 15: 481-5. PMID 1520797 |
0.046 |
|
| 1986 |
Wittmann DH, Kuipers TH, Fock R, Höll M, Bauernfeind A. Bone concentrations of imipenem following the imipenem/cilastatin infusion | Knochenkonzentrationen von Imipenem nach Gabe von Imipenem/Cilastatin Infection. 14: S130-S137. PMID 3463540 DOI: 10.1007/BF01647497 |
0.045 |
|
| 2009 |
Luque Fernández MA, Bauernfeind A. Reply to comment on: Influence of temperature and rainfall on the evolution of cholera epidemics in Lusaka, Zambia, 2003-2006: analysis of a time series Transactions of the Royal Society of Tropical Medicine and Hygiene. 103: 1183-1184. DOI: 10.1016/j.trstmh.2009.06.009 |
0.045 |
|
| 1990 |
Bellido F, Veuthey C, Blaser J, Bauernfeind A, Pechère JC. Novel resistance to imipenem associated with an altered PBP-4 in a Pseudomonas aeruginosa clinical isolate. The Journal of Antimicrobial Chemotherapy. 25: 57-68. PMID 2108115 |
0.045 |
|
| 1996 |
Bauernfeind A, Grimm H, Klietmann W, Opferkuch W, Werner H. The influence of sulbactam on the in vitro activity of mezlocillin, piperacillin and cefotaxime. International Journal of Antimicrobial Agents. 6: S15-26. PMID 18611715 |
0.045 |
|
| 1996 |
Abele-Horn M, Becher C, Bauernfeind A, Gerber B, Uhlig T, Roos R, Hentschel J, Peters J, Emmerling P. Comparative in vitro susceptibility of Ureaplasma urealyticum and Mycoplasma hominis to macrolides, tetracyclines, 4-quinolones, chloramphenicol, gentamicin, and clindamycin Antiinfective Drugs and Chemotherapy. 14: 171-173. |
0.045 |
|
| 2014 |
Schneider I, Markovska R, Marteva-Proevska Y, Mitov I, Markova B, Bauernfeind A. Detection of CMY-99, a novel acquired AmpC-Type β-lactamase, and VIM-1 in Proteus mirabilis isolates in Bulgaria. Antimicrobial Agents and Chemotherapy. 58: 620-1. PMID 24165184 DOI: 10.1128/AAC.01450-13 |
0.045 |
|
| 1986 |
Bauernfeind A. In-vitro-Aktivität und Resistenz bei 4-Chinolonen Infection. 14: S186-S187. PMID 3531027 DOI: 10.1007/BF01667840 |
0.045 |
|
| 1999 |
Bauernfeind A, Giamarellou H. Gatifloxacin: Viewpoints Drugs. 58: 697-698. |
0.045 |
|
| 1989 |
Bornschein W, Heilmann KL, Bauernfeind A, Przyklenk B. The pathogenetic and diagnostic significance of intragastric ammonia in active Campylobacter pylori associated gastritis Gastroduodenal Pathology and Campylobacter Pylori: Proceedings of the First Meeting of the European Campylobacter Pylori Study Group. Ics847. 401-404. |
0.044 |
|
| 1991 |
Bauernfeind A, Grimm H, Klietmann W, Opferkuch W, Werner H. [The effect of sulbactam on the in vitro activity of mezlocillin, piperacillin and cefotaxime]. Arzneimittel-Forschung. 41: 831-8. PMID 1781806 |
0.044 |
|
| 2009 |
Luque Fernández MA, Bauernfeind A, Jiménez JD, Gil CL, El Omeiri N, Guibert DH. Influence of temperature and rainfall on the evolution of cholera epidemics in Lusaka, Zambia, 2003-2006: analysis of a time series. Transactions of the Royal Society of Tropical Medicine and Hygiene. 103: 137-43. PMID 18783808 DOI: 10.1016/j.trstmh.2008.07.017 |
0.043 |
|
| 1996 |
Bauernfeind A, Stemplinger I, Jungwirth R, Wilhelm R, Chong Y. Comparative characterization of the cephamycinase blaCMY-1 gene and its relationship with other beta-lactamase genes. Antimicrobial Agents and Chemotherapy. 40: 1926-30. PMID 8843306 |
0.043 |
|
| 1998 |
Bauernfeind A, Jungwirth R. In vitro activity of novel fluoroquinolones against pathogens causing nosocomial respiratory tract infections | In-vitro-aktivitat neuerer Fluorchinolone gegenuber erregern nosokomialer atemwegsinfektionen Chemotherapie Journal. 7: 86-92. |
0.042 |
|
| 2012 |
Markovska R, Schneider I, Marteva-Proevsk Y, Mitov I, Bauernfeind A, Markova B. First detection of the AmpC beta-lactamase ACC-1 in a Klebsiella pneumoniae isolate in Bulgaria. Journal of Chemotherapy (Florence, Italy). 24: 307-8. PMID 23182053 DOI: 10.1179/1973947812Y.0000000025 |
0.042 |
|
| 1996 |
Bauernfeind A. Antibiotic susceptibility patterns of respiratory isolates of Klebsiella pneumoniae in Europe and the USA in 1992 and 1993. The Alexander Project Collaborative Group. The Journal of Antimicrobial Chemotherapy. 38: 107-15. PMID 8858477 |
0.042 |
|
| 1994 |
Cornaglia G, Ligozzi M, Bauernfeind A, Satta G, Fontana R. PBP binding and periplasmic concentration as determinants of the antibacterial activities of three new oral cephalosporins in Escherichia coli. The New Microbiologica. 17: 203-10. PMID 7968655 |
0.042 |
|
| 1987 |
Bauernfeind A, Rotter K, Weisslein-Pfister C. Selective procedure to isolate Haemophilus influenzae from sputa with large quantities of pseudomonas aeruginosa Infection. 15: 278-280. PMID 3117701 DOI: 10.1007/BF01644138 |
0.042 |
|
| 1998 |
Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Döring G, von der Hardt H. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatric Pulmonology. 25: 88-92. PMID 9516091 DOI: 10.1002/(Sici)1099-0496(199802)25:2<88::Aid-Ppul3>3.0.Co;2-J |
0.041 |
|
| 1992 |
Markus A, Klesel N, Wollmann T, Isert D, Limbert M, Schrinner E, Seibert G, Bauernfeind A, Jungwirth R, Wilhelm R. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. II. Stability to beta-lactamases and affinity for penicillin-binding proteins. The Journal of Antibiotics. 45: 521-6. PMID 1592684 |
0.041 |
|
| 2002 |
Wagenlehner FM, Krcmery S, Held C, Klare I, Witte W, Bauernfeind A, Schneider I, Naber KG. Epidemiological analysis of the spread of pathogens from a urological ward using genotypic, phenotypic and clinical parameters. International Journal of Antimicrobial Agents. 19: 583-91. PMID 12135852 DOI: 10.1016/S0924-8579(02)00093-6 |
0.041 |
|
| 1998 |
Bauernfeind A. Errata: Comparison of the antibacterial profiles of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin (Journal of Antimicrobial Chemotherapy (1997) 40 (639-651)) Journal of Antimicrobial Chemotherapy. 41: 672. |
0.04 |
|
| 2005 |
AktaÅŸ Z, Gönüllü N, Schneider I, Bal C, Bauernfeind A. [Detection of CTX-M-15 type extended spectrum beta-lactamase in an Escherichia coli strain isolated from the urine sample of a hospitalized patient]. Mikrobiyoloji Bã¼Lteni. 39: 421-9. PMID 16544543 |
0.04 |
|
| 1986 |
Naber KG, Adam D, Bauernfeind A, Hönig E. Imipenem/cilastatin: In vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infection | Imipenem/Cilastatin: In vitro-Aktivität, Konzentrationen in Plasma und Prostataadenom sowie Therapieergebnisse bei Patienten mit komplizierten Harnwegsinfektionen Infection. 14: S122-S129. PMID 2428754 DOI: 10.1007/BF01647496 |
0.04 |
|
| 1999 |
Sahly H, Boehme V, Podschun R, Bauernfeind A, Fölsch UR, Ullmann U. Infection and chronic colonization of an intensive care unit patient's respiratory tract by a Klebsiella pneumoniae strain producing a novel AmpC beta-lactamase different from that known. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 28: 1338-9. PMID 10451189 DOI: 10.1086/517795 |
0.039 |
|
| 1992 |
Neu HC, Kawada Y, Stamm WE, Norrby SR, Schaeffer AJ, Westenfelder M, Naber KG, Bailey RR, Janknegt RA, Pfau A, Andriole VT, Bauernfeind A, Bergan T, Robson RA, Newsom SWB, et al. General discussion session V on international guidelines for uncomplicated and complicated UTI Infection. 20: S195-S202. DOI: 10.1007/BF01704374 |
0.039 |
|
| 1988 |
Bauernfeind A, Eberleinn E, Horl G. Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures Journal of Antimicrobial Chemotherapy. 22: 81-89. PMID 3144553 |
0.038 |
|
| 1996 |
Naber KG, Witte W, Bauernfeind A. In vitro activity of aminoglycosides against pathogens causing complicated urinary tract infections | IN-VITRO-AKTIVITAT VON AMINOGLYKOSIDEN GEGEN ERREGER VON KOMPLIZIERTEN HARNWEGSINFEKTIONEN Chemotherapie Journal. 5: 64-66. |
0.038 |
|
| 1998 |
Gniadkowski M, Schneider I, Pałucha A, Jungwirth R, Mikiewicz B, Bauernfeind A. Cefotaxime-resistant Enterobacteriaceae isolates from a hospital in Warsaw, Poland: identification of a new CTX-M-3 cefotaxime-hydrolyzing beta-lactamase that is closely related to the CTX-M-1/MEN-1 enzyme. Antimicrobial Agents and Chemotherapy. 42: 827-32. PMID 9559791 |
0.038 |
|
| 1997 |
Abele-Horn M, Dauber A, Bauernfeind A, Russwurm W, Seyfarth-Metzger I, Gleich P, Ruckdeschel G. Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination (SOD). Intensive Care Medicine. 23: 187-95. PMID 9069004 DOI: 10.1007/s001340050314 |
0.038 |
|
| 1995 |
Bauernfeind A, Jungwirth R, Eberlein E. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Infection. 23: 316-21. PMID 8557398 DOI: 10.1007/BF01716300 |
0.037 |
|
| 1996 |
Bauernfeind A, Stemplinger I, Jungwirth R, Mangold P, Amann S, Akalin E, AnÄŸ O, Bal C, Casellas JM. Characterization of beta-lactamase gene blaPER-2, which encodes an extended-spectrum class A beta-lactamase. Antimicrobial Agents and Chemotherapy. 40: 616-20. PMID 8851581 |
0.037 |
|
| 1996 |
Grüneberg RN, Felmingham D, Acar J, Lemozy J, Bauernfeind A, Grimm H, Schito GC, Russo G, Baquero F, Linares Louzao J, Grütineberg R, Murphy P, Neu H, Chin UX, Washington J, et al. Results of the Alexander Project: A continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens Diagnostic Microbiology and Infectious Disease. 25: 169-181. PMID 8937841 DOI: 10.1016/S0732-8893(96)00135-6 |
0.037 |
|
| 2009 |
Schneider I, Queenan AM, Markovska R, Markova B, Keuleyan E, Bauernfeind A. New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. Antimicrobial Agents and Chemotherapy. 53: 4518-21. PMID 19620330 DOI: 10.1128/Aac.00461-09 |
0.036 |
|
| 1986 |
Löffler L, Bauernfeind A, Keyl W, Hoffstedt B, Piergies A, Lenz W. An open, comparative study of sulbactam plus ampicillin vs. cefotaxime as initial therapy for serious soft tissue and bone and joint infections. Reviews of Infectious Diseases. 8: S593-8. PMID 3026009 |
0.036 |
|
| 1994 |
Bauernfeind A, Abele-Horn M, Emmerling P, Jungwirth R. Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae. The Journal of Antimicrobial Chemotherapy. 34: 1074-6. PMID 7730225 DOI: 10.1093/jac/34.6.1074 |
0.036 |
|
| 1997 |
Fille M, Allerberger F, Prodinger WM, Dierich MP, Speer G, Bauernfeind A. SHV-5 beta-lactamase producing Klebsiella pneumoniae isolates | SHV-5-Beta-Lactamase-bildende Klebsiella-pneumoniae-Isolate Chemotherapie Journal. 6: 71-75. |
0.035 |
|
| 1998 |
Bauernfeind A, Chong Y, Lee K. Plasmid-encoded AmpC beta-lactamases: how far have we gone 10 years after the discovery? Yonsei Medical Journal. 39: 520-5. PMID 10097678 |
0.035 |
|
| 1986 |
Bauernfeind A, Flamm H, Grimm H, Hahn H, Kayser F, Opferkuch W, Potel J, Malottke R, Sonntag HG, Traub WH, Ullmann U, Wiedemann B. Enoxacin: Spektrum und Aktivität seiner antibakteriellen Wirkung Infection. 14: S188-S190. PMID 3531028 DOI: 10.1007/BF01667841 |
0.035 |
|
| 1989 |
Bornschein W, Heilmann KL, Bauernfeind A. [Intragastric formation of ammonia in Campylobacter pylori associated gastritis. Diagnostic and pathogenetic significance]. Medizinische Klinik (Munich, Germany : 1983). 84: 329-32, 368. PMID 2677629 |
0.034 |
|
| 1999 |
Bauernfeind A, Schneider I, Jungwirth R, Roller C. Discrimination of Burkholderia multivorans and Burkholderia vietnamiensis from Burkholderia cepacia genomovars I, III, and IV by PCR. Journal of Clinical Microbiology. 37: 1335-9. PMID 10203482 |
0.034 |
|
| 2007 |
Rymer J, Bauernfeind AL, Brown S, Page TL. Circadian rhythms in the mating behavior of the cockroach, Leucophaea maderae. Journal of Biological Rhythms. 22: 43-57. PMID 17229924 DOI: 10.1177/0748730406295462 |
0.034 |
|
| 1999 |
Schito GC, Auckenthaler R, Marchese A, Bauernfeind A. European survey of glycopeptide susceptibility in Staphylococcus spp. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 5: 547-553. PMID 11851707 |
0.034 |
|
| 1991 |
Bauernfeind A, Schweighart S, Eberlein E, Jungwirth R. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin). Infection. 19: S264-75. PMID 1664418 DOI: 10.1007/BF01645538 |
0.034 |
|
| 2008 |
Luque Fernández MA, Bauernfeind A, Palma Urrutia PP, Ruiz Pérez I. [Frequency of sexually transmitted infections and related factors in Pweto, Democratic Republic of Congo, 2004]. Gaceta Sanitaria / S.E.S.P.a.S. 22: 29-34. PMID 18261439 DOI: 10.1157/13115107 |
0.034 |
|
| 1997 |
Grimm H, Bauernfeind A. The Alexander Project - An international study on antibiotic sensitivity of bacterial pathogens in community-acquired respiratory tract infections | Das Alexander-Projekt - Eine internationale Studie uber Antibiotika-Sensibilitat bakterieller Erreger bei ambulant erworbenen Atemwegsinfektionen Antiinfective Drugs and Chemotherapy. 15: 93-98. |
0.033 |
|
| 1996 |
Bauernfeind A. Activity of meropenem, imipenem and ceftazidime in Pseudomonas aeruginosa and Burkholderia cepacia of patients with mucoviscidosis | AKTIVITAT VON MEROPENEM, IMIPENEM UND CEFTAZIDIM BEI PSEUDOMONAS AERUGINOSA UND BURKHOLDERIA CEPACIA VON PATIENTEN MIT MUKOVISZIDOSE Chemotherapie Journal, Supplement. 5: 25-27. |
0.033 |
|
| 2007 |
Schneider I, Markovska R, Keuleyan E, Sredkova M, Rachkova K, Mitov I, Bauernfeind A. Dissemination and persistence of a plasmid-mediated TEM-3-like beta-lactamase, TEM-139, among Enterobacteriaceae in Bulgaria. International Journal of Antimicrobial Agents. 29: 710-4. PMID 17382521 DOI: 10.1016/j.ijantimicag.2006.12.014 |
0.032 |
|
| 1998 |
Gniadkowski M, Schneider I, Jungwirth R, Hryniewicz W, Bauernfeind A. Ceftazidime-resistant Enterobacteriaceae isolates from three Polish hospitals: identification of three novel TEM- and SHV-5-type extended-spectrum beta-lactamases. Antimicrobial Agents and Chemotherapy. 42: 514-20. PMID 9517925 |
0.032 |
|
| 1989 |
Bauernfeind A, Chong Y, Schweighart S. Extended broad spectrum beta-lactamase in Klebsiella pneumoniae including resistance to cephamycins. Infection. 17: 316-21. PMID 2689349 DOI: 10.1007/BF01650718 |
0.031 |
|
| 1992 |
Bauernfeind A, Jungwirth R, Eberlein E, Klesel N, Adam F, Isert D, Limbert M, Markus A, Schrinner E, Seibert G. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro. The Journal of Antibiotics. 45: 505-20. PMID 1592683 |
0.03 |
|
| 1993 |
Steimer W, Przyklenk B, Bauernfeind A. Processing raw absorbance data generated by ELISA for measuring specific antibody activity Serodiagnosis and Immunotherapy in Infectious Disease. 5: 53-59. DOI: 10.1016/0888-0786(93)90026-V |
0.03 |
|
| 1992 |
van den Wijngaart W, Verbrugh H, Theopold HM, Bauernfeind A, Cuenant G, Duval I, Wilber RB, Durham SJ, Hamilton H, Van Gysel P. A noncomparative study of cefprozil at two dose levels in the treatment of acute uncomplicated bacterial sinusitis. Clinical Therapeutics. 14: 306-13. PMID 1611651 |
0.03 |
|
| 1990 |
Bauernfeind A, Jungwirth R, Schweighart S, Theopold M. [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins]. Infection. 18: S155-67. PMID 2079378 DOI: 10.1007/BF01644637 |
0.03 |
|
| 1996 |
Struelens MJ, Bauernfeind A, Van Belkum A, Blanc D, Cookson BD, Dijkshoorn L, El Solh N, Etienne J, Garaizar J, Gerner-Smidt P, Legakis N, De Lencastre H, Nicolas MH, Pitt TL, Römling U, et al. Consensus guidelines for appropriate use and evaluation of microbial epidemiologic typing systems Clinical Microbiology and Infection. 2: 2-11. |
0.03 |
|
| 2019 |
Ebertz DP, Onufer EJ, Salimpour A, Allen K, Bauernfeind A, Awad MM. Bringing Medical Education into the 21st Century with an Electronic Study Tool Journal of the American College of Surgeons. 229: e181. DOI: 10.1016/j.jamcollsurg.2019.08.1224 |
0.03 |
|
| 1998 |
Goldstein F, Bryskier A, Appelbaum PC, Bauernfeind A, Jacobs M, Schito GC, Wise R. The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral antibacterial agents against respiratory pathogens. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 4: S8-S18. PMID 11869250 |
0.03 |
|
| 1999 |
Bauernfeind A, Schneider I, Jungwirth R, Sahly H, Ullmann U. A novel type of AmpC beta-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia. Antimicrobial Agents and Chemotherapy. 43: 1924-31. PMID 10428914 |
0.029 |
|
| 2003 |
Bufler P, Schmidt B, Schikor D, Bauernfeind A, Crouch EC, Griese M. Surfactant protein A and D differently regulate the immune response to nonmucoid Pseudomonas aeruginosa and its lipopolysaccharide. American Journal of Respiratory Cell and Molecular Biology. 28: 249-56. PMID 12540493 DOI: 10.1165/rcmb.4896 |
0.029 |
|
| 2012 |
Markovska R, Keuleyan E, Ivanova D, Markova B, Proevska J, Leseva M, Sredkova M, Schneider I, Bauernfeind A, Mitov I. Dissemination of CTX-mextended spectrum beta-lactamase producing isolates of Klebsiella pneumoniae in four hospitals in Sofia and Pleven Problems of Infectious and Parasitic Diseases. 40: 5-9. |
0.029 |
|
| 2015 |
Markovska R, Stoeva T, Schneider I, Boyanova L, Popova V, Dacheva D, Kaneva R, Bauernfeind A, Mitev V, Mitov I. Clonal dissemination of multilocus sequence type ST15 KPC-2-producing Klebsiella pneumoniae in Bulgaria. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 123: 887-94. PMID 26303718 DOI: 10.1111/apm.12433 |
0.028 |
|
| 2013 |
Markovska R, Schneider I, Stoeva T, Bojkova K, Boyanova L, Bauernfeind A, Mitov I. First identification of KPC-2 and VIM-1 producing Klebsiella pneumoniae in Bulgaria. Diagnostic Microbiology and Infectious Disease. 77: 252-3. PMID 24041551 DOI: 10.1016/j.diagmicrobio.2013.07.019 |
0.028 |
|
| 1985 |
Weissenbacher ER, Gutschow K, Bauernfeind A, Lūehr HG. Temocillin Treatment of Gynaecological Infections with Special Reference to Blood and Tissue Concentrations Drugs. 29: 178-181. PMID 3896737 DOI: 10.2165/00003495-198500295-00038 |
0.028 |
|
| 1989 |
Bornschein W, Bauernfeind A, Heilmann KL. Detection of campylobacter pylori: Correlation of clinical, bacteriological, histological, enzymatic (urease) and chemical (urea) parameters | UREASE-SCHNELLTESTES BEI CAMPYLOBACTER-PYLORI-BESIEDLUNG DER MAGENSCHLEIMHAUT Gastroenterologisches Journal. 49: 54-58. PMID 2679659 |
0.028 |
|
| 2007 |
Fernández MAL, Bauernfeind A. Prevencion of maternal mortality: An example on community intervention in Congo | Prevención de la mortalidad materna. Un ejemplo de intervención comunitaria en salud en el Congo Index De Enfermeria. 16. |
0.027 |
|
| 1996 |
Bauernfeind A. Extended spectrum -lactamases in enterobacteriaceae Medical Microbiology Letters. 5: 439-443. |
0.027 |
|
| 1993 |
Bauernfeind A. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. The Journal of Antimicrobial Chemotherapy. 31: 505-22. PMID 7605398 DOI: 10.1093/jac/31.4.505 |
0.026 |
|
| 1997 |
Bauernfeind A, Wagner S, Jungwirth R, Schneider I, Meyer D. A novel class C beta-lactamase (FOX-2) in Escherichia coli conferring resistance to cephamycins. Antimicrobial Agents and Chemotherapy. 41: 2041-6. PMID 9303413 |
0.026 |
|
| 1987 |
Naber KG, Bauernfeind A, Dietlein G, Wittenberger R. Spectrum and sensitivities of agents of urinary tract infections in urologic patients in hospital: Correlation with clinical aspects | SPEKTRUM UN SENSIBILITAT DER ERREGER VON HARNWEGSINFEKTIONEN BEI STATIONAREN UROLOGISCHEN PATIENTEN IN KORRELATION ZU KLINISCHEN ASPEKTEN Urologe - Ausgabe B. 27: 157-164. |
0.025 |
|
| 2004 |
Markovska R, Schneider I, Keuleyan E, Bauernfeind A. Extended-spectrum beta-lactamase (ESBL) CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae in Sofia, Bulgaria. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 10: 752-5. PMID 15301679 DOI: 10.1111/j.1469-0691.2004.00929.x |
0.025 |
|
| 1987 |
Naber K, Kees F, Denk K, Bauernfeind A, Grobecker H. Carumonam versus ceftazidime: in vitro activity, pharmacokinetics in elderly patients, safety and therapeutic efficacy in the treatment of complicated urinary tract infections Chemioterapia. 6: 517-518. PMID 3334613 |
0.024 |
|
| 1988 |
Löffler L, Bauernfeind A, Keyl W. Sulbactam/Ampicillin versus Cefotaxime as Initial Therapy in Serious Soft Tissue, Joint and Bone Infections Drugs. 35: 46-52. PMID 3265378 DOI: 10.2165/00003495-198800357-00012 |
0.024 |
|
| 1998 |
Naber KG, Vogel F, Scholz H, Adam D, Bauernfeind A, Elies W, Gortz G, Helwig H, Knothe H, Lode H, Petersen EE, Stille W, Tauchnitz C, Ullmann U, Wiedemann B. Rational application of oral antibiotic agents in the practice | Rationaler einsatz oraler antibiotika in der praxis. Empfehlungen einer expertenkommission der Paul-Ehrlich-Gesellschaft fur chemotherapie e.V Chemotherapie Journal. 7: 16-26. |
0.024 |
|
| 2006 |
Damjanova I, Tóth A, Pászti J, Bauernfeind A, Füzi M. Nationwide spread of clonally related CTX-M-15-producing multidrug-resistant Klebsiella pneumoniae strains in Hungary. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 25: 275-8. PMID 16565826 DOI: 10.1007/S10096-006-0120-4 |
0.023 |
|
| 1992 |
Bauernfeind A, Casellas JM, Goldberg M, Holley M, Jungwirth R, Mangold P, Röhnisch T, Schweighart S, Wilhelm R. A new plasmidic cefotaximase from patients infected with Salmonella typhimurium. Infection. 20: 158-63. PMID 1644493 DOI: 10.1007/BF01704610 |
0.023 |
|
| 1996 |
Bauernfeind A, Stemplinger I, Jungwirth R, Ernst S, Casellas JM. Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases. Antimicrobial Agents and Chemotherapy. 40: 509-13. PMID 8834913 |
0.023 |
|
| 2005 |
Markovska R, Rachkova K, Schneider I, Keuleyan E, Bauernfeind A. Multiresistant SHV-2-producing Salmonella enterica Serotype Corvallis in Bulgaria. Journal of Chemotherapy (Florence, Italy). 17: 568-9. PMID 16323450 DOI: 10.1179/joc.2005.17.5.568 |
0.023 |
|
| 1996 |
Walter S, Knüpfer M, Lietz T, Schille R, Handrick W, Spencker FB, Bauernfeind A. Retrospective study about respiratory microbial pathogens in children with cystic fibrosis | retrospektive studie uber den nachweis pathogener erreger im respirationstrakt von kindern mit zystischer fibrose Pediatrics and Related Topics. 35: 333-340. |
0.022 |
|
| 1990 |
Bauernfeind A. Perspectives of beta-lactamases inhibitors in therapy of infections caused by Escherichia coli or Klebsiella with plasmidic resistance to third generation cephalosporins. Infection. 18: 48-52. PMID 2179138 DOI: 10.1007/BF01644185 |
0.022 |
|
| 1986 |
Bauernfeind A. Classification of beta-lactamases Reviews of Infectious Diseases. 8: S470-481. PMID 3541132 |
0.022 |
|
| 1996 |
Semina NE, Bauernfeind A. Identification of extended spectrum (ES) betalactamase producing klebsiella pneumoniae strains in Russia Medical Microbiology Letters. 5: S30. |
0.022 |
|
| 1996 |
Prodinger WM, Fille M, Bauernfeind A, Stemplinger I, Amann S, Pfausler B, Lass-Florl C, Dierich MP. Molecular epidemiology of Klebsiella pneumoniae producing SHV-5 beta- lactamase: parallel outbreaks due to multiple plasmid transfer. Journal of Clinical Microbiology. 34: 564-8. PMID 8904415 |
0.021 |
|
| 1996 |
Adam D, Grimm H, Lode H, Bauernfeind A. Re: A. Bauernfeind et al.: Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens (Infection 23 [1995] 316-321) [3] Infection. 24: 270-271. PMID 8811372 |
0.021 |
|
| 1987 |
Bauernfeind A, Naber K, Sauerwein D. Spectrum of bacterial pathogens in uncomplicated and complicated urinary tract infections European Urology. 13: 9-12. PMID 3552704 |
0.021 |
|
| 1992 |
Eitel F, Bauernfeind A, Lang E. Teicoplanin in the therapy of bone and joint infections Current Therapeutic Research - Clinical and Experimental. 51: 97-111. |
0.02 |
|
| 1998 |
Bauernfeind A, Roller C, Meyer D, Jungwirth R, Schneider I. Molecular procedure for rapid detection of Burkholderia mallei and Burkholderia pseudomallei. Journal of Clinical Microbiology. 36: 2737-41. PMID 9705426 |
0.02 |
|
| 1992 |
Ritter E, Bauernfeind A, Becker-Boost E, Fiehn A, Stöcker H, Wirsing von König CH, Finger H. [Outbreak of a nosocomial infection of SHV2-beta-lactamase-containing Klebsiella pneumonia strains in an operative intensive care unit]. Immunitã¤T Und Infektion. 20: 3-6. PMID 1563756 |
0.02 |
|
| 2008 |
Ivanova D, Markovska R, Hadjieva N, Schneider I, Mitov I, Bauernfeind A. Extended-spectrum beta-lactamase-producing Serratia marcescens outbreak in a Bulgarian hospital. The Journal of Hospital Infection. 70: 60-5. PMID 18602186 DOI: 10.1016/j.jhin.2008.04.033 |
0.02 |
|
| 2008 |
AktaÅŸ Z, Kayacan CB, Schneider I, Can B, Midilli K, Bauernfeind A. Carbapenem-hydrolyzing oxacillinase, OXA-48, persists in Klebsiella pneumoniae in Istanbul, Turkey. Chemotherapy. 54: 101-6. PMID 18303258 DOI: 10.1159/000118661 |
0.02 |
|
| 1995 |
Casellas JM, Bauernfeind A, Goldberg M, Cuba J, Merino S, Gilardoni M, San Juan J. Therapeutical error in Klebsiella pneumoniae bacteremia treated with cefepime and amikacin | FALLO TERAPEUTICO EN UNA BACTERIEMIA POR KLEBSIELLA PNEUMONIAE TRATADA CON CEFEPIMA Y AMIKACINA Revista Espanola De Quimioterapia. 8: 327-328. |
0.019 |
|
| 1989 |
Bauernfeind A, Przyklenk B, Horl G, Otto U. Representative Campylobacter pylori antigen for IgG-ELISA and diagnostic significance of antibody titres Gastroduodenal Pathology and Campylobacter Pylori: Proceedings of the First Meeting of the European Campylobacter Pylori Study Group. Ics847. 185-188. |
0.019 |
|
| 1986 |
Bauernfeind A, Petermüller C, Heinrich B, Gablac R. Bactericidal kinetics and selection of resistant mutants by 4-quinolones at concentrations following their serum pharmacokinetics | Abhängigkeit von Bakterizidie und Mutantenselektion bei 4-Chinolonen von deren Serumkonzentrationsverläufen Infection. 14: S26-S30. PMID 3082765 DOI: 10.1007/BF01645194 |
0.019 |
|
| 1999 |
Bauernfeind A, Jungwirth R, Ratjen F. Susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients to ciprofloxacin Drugs. 58: 209-210. DOI: 10.2165/00003495-199958002-00063 |
0.019 |
|
| 1992 |
Kljucar S, Heimesaat M, Von Pritzbuer E, Timm J, Bauernfeind A. A comparison of intravenous ciprofloxacin dosage regimens in severe nosocomial infections Infections in Medicine. 9: 58-72. |
0.019 |
|
| 1996 |
Bauernfeind A. [Plasmidic extended spectrum resistance to beta-lactams in nosocomial infections]. KansenshåGaku Zasshi. the Journal of the Japanese Association For Infectious Diseases. 70: 1211-9. PMID 9011113 |
0.019 |
|
| 2006 |
Markovska R, Keuleyan E, Schneider I, Markova B, Rachkova K, Sredkova M, Bauernfeind A. CTX-M-3 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and dissemination of the plasmidic blaCTX-M-3 in Bulgaria. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 25: 123-5. PMID 16489427 DOI: 10.1007/s10096-006-0085-3 |
0.018 |
|
| 1989 |
Ulrich E, Trautmann M, Krause B, Bauernfeind A, Hahn H. Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice. Infection. 17: 311-5. PMID 2599653 DOI: 10.1007/BF01650716 |
0.018 |
|
| 2008 |
Markovska R, Schneider I, Keuleyan E, Sredkova M, Ivanova D, Markova B, Lazarova G, Dragijeva E, Savov E, Haydouchka I, Hadjieva N, Setchanova L, Mitov I, Bauernfeind A. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in Bulgarian hospitals. Microbial Drug Resistance (Larchmont, N.Y.). 14: 119-28. PMID 18489242 DOI: 10.1089/mdr.2008.0814 |
0.017 |
|
| 2011 |
Keuleyan E, Tete S, Valentinova M, Markovska R, Anakieva T, Schneider I, Bauernfeind A. ESBL - producing enterobacteriaceae - an increasing problem among patients with bacteremia Problems of Infectious and Parasitic Diseases. 39: 5-8. |
0.017 |
|
| 2012 |
Markovska R, Schneider I, Ivanova D, Keuleyan E, Stoeva T, Sredkova M, Markova B, Bojkova K, Gergova R, Bauernfeind A, Mitov I. High prevalence of CTX-M-15-producing O25b-ST131 Escherichia coli clone in Bulgarian hospitals. Microbial Drug Resistance (Larchmont, N.Y.). 18: 390-5. PMID 22352448 DOI: 10.1089/mdr.2011.0186 |
0.017 |
|
| 1990 |
Przyklenk B, Bauernfeind A, Bornschein W, Emminger G, Heilmann K, Schweighart S. The role of Campylobacter (Helicobacter) pylori in disorders of the gastrointestinal tract. Infection. 18: 3-7. PMID 2312173 DOI: 10.1007/BF01644170 |
0.017 |
|
| 1994 |
Bauernfeind A, Thornsberry C, Grassi GG, Painter BG, Peters G, Shlaes DM, Stratton CW. Panel discussion: Quinolone resistance in gram-positive bacteria Infectious Diseases in Clinical Practice. 3: S133-S135. |
0.016 |
|
| 1994 |
Naber KG, Witte W, Bauernfeind A, Wiedemann B, Wagenlehner F, Klare I, Heisig P. Clinical significance and spread of fluoroquinolone resistant uropathogens in hospitalised urological patients. Infection. 22: S122-7. PMID 7927830 DOI: 10.1007/BF01793576 |
0.016 |
|
| 1987 |
Naber KG, Bauernfeind A, Dietlein G, Wittenberger R. Urinary pathogens and bacterial sensitivity in hospitalized urological patients based upon clinical aspects Scandinavian Journal of Urology and Nephrology, Supplement. 104: 47-57. PMID 3501901 |
0.016 |
|
| 1994 |
Ritter E, Thurm V, Bauernfeind A, Dorittke C, Völpel S, Finger H. [Nosocomial colonization and infection by multiresistant Enterobacter cloacae strains on a pediatric oncological unit]. Zentralblatt Fã¼R Hygiene Und Umweltmedizin = International Journal of Hygiene and Environmental Medicine. 196: 81-94. PMID 7802900 |
0.016 |
|
| 1998 |
Ritter E, Bauernfeind A, Dorittke C, Feller R. [Frequency and antibiotic susceptibility of oxacillin resistant Staphylococcus aureus in a teaching hospital]. Zentralblatt Fã¼R Hygiene Und Umweltmedizin = International Journal of Hygiene and Environmental Medicine. 201: 285-96. PMID 9789363 |
0.015 |
|
| 1990 |
Bauernfeind A, Przyklenk B, Matthias C, Jungwirth R, Bertele RM, Harms K. Selection of antibiotics for treatment and prophylaxis of staphylococcal infections in cystic fibrosis patients. Infection. 18: 126-30. PMID 2332248 DOI: 10.1007/BF01641436 |
0.014 |
|
| 1993 |
Naber KG, Witte W, Bauernfeind A, Wiedemann B. Emergence of Resistance of Uropathogens to Quinolones Drugs. 45: 177-178. DOI: 10.2165/00003495-199300453-00038 |
0.014 |
|
| 1987 |
Bauernfeind A, Hörl G, Jungwirth R, Petermüller C, Przyklenk B, Weisslein-Pfister C, Bertele RM, Harms K. Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis Infection. 15: 270-277. PMID 3117700 DOI: 10.1007/BF01644137 |
0.014 |
|
| 1996 |
Naber KG, Witte W, Bauernfeind A. Therapy of complicated urinary tract infections | Therapie komplizierter Harnwegsinfektionen Nieren- Und Hochdruckkrankheiten. 25: 567-571. |
0.014 |
|
| 1996 |
Bauernfeind A, Stemplinger I, Jungwirth R, Giamarellou H. Characterization of the plasmidic beta-lactamase CMY-2, which is responsible for cephamycin resistance. Antimicrobial Agents and Chemotherapy. 40: 221-4. PMID 8787910 |
0.014 |
|
| 2010 |
Tayler-Smith K, Zachariah R, Massaquoi M, Manzi M, Pasulani O, van den Akker T, Bemelmans M, Bauernfeind A, Mwagomba B, Harries AD. Unacceptable attrition among WHO stages 1 and 2 patients in a hospital-based setting in rural Malawi: can we retain such patients within the general health system? Transactions of the Royal Society of Tropical Medicine and Hygiene. 104: 313-9. PMID 20138323 DOI: 10.1016/j.trstmh.2010.01.007 |
0.013 |
|
| 1985 |
Inthorn D, Bauernfeind A. Postoperative antibiotic therapy | POSTOPERATIVE ANTIBIOTICATHERAPIE Chirurg. 56: 558-563. PMID 3902393 |
0.013 |
|
| 1996 |
Kempf P, Bauernfeind A, Müller A, Blum J. Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. Infection. 24: 473-9. PMID 9007598 |
0.013 |
|
| 1997 |
Bauernfeind A, Marks MI, Strandwik B. Cystic fibrosis pulmonary infections: Lessons from around the world Pneumologie. 51: 541. |
0.013 |
|
| 1987 |
Naber K, Adam D, Bauernfeind A, Hönig E, Tiebel R. Imipenem in the treatment of complicated urinary tract infection Chemioterapia. 6: 511-512. PMID 3509485 |
0.013 |
|
| 1988 |
Bauernfeind A, Hörl G, Przyklenk B. Microbiologic and therapeutic aspects of staphylococcus aureus in cystic fibrosis patients Scandinavian Journal of Gastroenterology. 23: 99-102. PMID 3164518 DOI: 10.3109/00365528809090226 |
0.012 |
|
| 1993 |
Bauernfeind A, Rosenthal E, Eberlein E, Holley M, Schweighart S. Spread of Klebsiella pneumoniae producing SHV-5 beta-lactamase among hospitalized patients. Infection. 21: 18-22. PMID 8449575 DOI: 10.1007/BF01739303 |
0.011 |
|
| 1990 |
Przyklenk B, Bauernfeind A, Bornschein W, Gabor M. Evaluation of an IgG-ELISA-kit for diagnosing Helicobacter pylori associated gastroduodenal disease Serodiagnosis and Immunotherapy in Infectious Disease. 4: 263-269. DOI: 10.1016/0888-0786(90)90013-E |
0.011 |
|
| 2009 |
Massaquoi M, Zachariah R, Manzi M, Pasulani O, Misindi D, Mwagomba B, Bauernfeind A, Harries AD. Patient retention and attrition on antiretroviral treatment at district level in rural Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene. 103: 594-600. PMID 19298993 DOI: 10.1016/j.trstmh.2009.02.012 |
0.01 |
|
| 1987 |
Bauernfeind A, Przyklenk B. Spectrum of Pseudomonas aeruginosa O-serotypes from hospitalized patients and content of antibodies in sera of volunteers and in immunoglobulins Serodiagnosis and Immunotherapy in Infectious Disease. 1: 287-295. DOI: 10.1016/0888-0786(87)90008-4 |
0.01 |
|
| 1996 |
Allerberger F, Koeuth T, Lass-FLörl C, Dierich MP, Putensen C, Scmutzhard E, Mohsenipour I, Grundmann H, Hartung D, Bauernfeind A, Eberlein E, Lupski JR. Epidemiology of infections due to multiresistant Enterobacter aerogenes in a university hospital. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 15: 517-21. PMID 8839650 DOI: 10.1007/BF01691323 |
0.01 |
|
| 2014 |
Markovska R, Schneider I, Ivanova D, Mitov I, Bauernfeind A. Predominance of IncL/M and IncF plasmid types among CTX-M-ESBL-producing Escherichia coli and Klebsiella pneumoniae in Bulgarian hospitals. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 122: 608-15. PMID 24303846 DOI: 10.1111/apm.12204 |
0.01 |
|
| 2009 |
Möllmann U, Heinisch L, Bauernfeind A, Köhler T, Ankel-Fuchs D. Siderophores as drug delivery agents: application of the "Trojan Horse" strategy. Biometals : An International Journal On the Role of Metal Ions in Biology, Biochemistry, and Medicine. 22: 615-24. PMID 19214755 DOI: 10.1007/s10534-009-9219-2 |
0.01 |
|
| 2008 |
Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 7: 142-6. PMID 17766190 DOI: 10.1016/j.jcf.2007.07.001 |
0.01 |
|
| 2005 |
Otağ F, Ersöz G, Salcioğlu M, Bal C, Schneider I, Bauernfeind A. Nosocomial bloodstream infections with Burkholderia stabilis. The Journal of Hospital Infection. 59: 46-52. PMID 15571853 DOI: 10.1016/j.jhin.2004.06.034 |
0.01 |
|
| 2002 |
Jung A, Kleinau I, Schönian G, Bauernfeind A, Chen C, Griese M, Döring G, Göbel U, Wahn U, Paul K. Sequential genotyping of Pseudomonas aeruginosa from upper and lower airways of cystic fibrosis patients. The European Respiratory Journal. 20: 1457-63. PMID 12503704 DOI: 10.1183/09031936.02.00268002 |
0.01 |
|
| 1999 |
Bauernfeind A. Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae. The Journal of Antimicrobial Chemotherapy. 43: 77-82. PMID 10404343 |
0.01 |
|
| 1998 |
Fille M, Bauernfeind A, Eberlein E, Jungwirth R, Schneider I, Speer G, Dierich MP, Allerberger F. [Imipenem resistance in Pseudomonas aeruginosa]. Wiener Klinische Wochenschrift. 110: 715-20. PMID 9857429 |
0.01 |
|
| 1997 |
Bauernfeind A, Przyklenk B. Microbiological background for anti-Pseudomonas aeruginosa vaccination in cystic fibrosis. Behring Institute Mitteilungen. 256-61. PMID 9382748 |
0.01 |
|
| 1997 |
Spencer RC, Bauernfeind A, Garcia-Rodriguez J, Jarlier V, Pfaller M, Turnidge J, Voss A. Surveillance of the current resistance of nosocomial pathogens to antibacterials Clinical Microbiology and Infection. 3: S21-S35. |
0.01 |
|
| 1993 |
Bauernfeind A. Questioning dosing regimens of ciprofloxacin. The Journal of Antimicrobial Chemotherapy. 31: 789-98. PMID 8335507 DOI: 10.1093/jac/31.5.789 |
0.01 |
|
| 1993 |
Grimm H, Springsklee M, Schmalreck AF, Bauernfeind A, Focht J, Opferkuch W, Werner H. Susceptibility breakpoints for sensitivity testing of bacterial germs against mezlocillin/sulbactam, piperacillin/sulbactam, cefotaxime/sulbactam and cefoperazone/sulbactam in the agar diffusion test according to DIN 58940 | BEWERTUNGSGRENZEN FUR DIE EMPFINDLICHKEITSPRUFUNG BAKTERIELLER ERREGER GEGENUBER MEZLOCILLIN/SULBACTAM, PIPERACILLIN/SULBACTAM, CEFOTAXIM/SULBACTAM AND CEFOPERAZON/SULBACTAM IM AGAR-DIFFUSIONSTEST NACH DIN 58940 Zac Zeitschrift Fur Antimikrobielle Antineoplastische Chemotherapie. 11: 39-49. |
0.01 |
|
| 1992 |
Loirat P, Johanson WG, Van Saene HKF, Bauernfeind A, Binslev A, Falke K, Finch RG, Launois R, Reynaert M, Robotham JL, Tognoni G, Torres A, Van Der Meer JWM. Selective digestive decontamination in intensive care unit patients Intensive Care Medicine. 18: 182-188. PMID 1644969 DOI: 10.1007/BF01709246 |
0.01 |
|
| 1990 |
Bauernfeind A, Przyklenk B, Eberlein E, Jungwirth R, Bertele R, Harms K. The antibiotic susceptibility of Pseudomonas aeruginosa from sputa and throat swabs of cystic fibrosis patients Revista Espanola De Quimioterapia. 3: 261-264. |
0.01 |
|
| 1989 |
Przyklenk B, Bauernfeind A, Bornschein W, Bertele RM, Harms K, Arleth S. Seroimmunological monitoring of Campylobacter pylori in patients with cystic fibrosis Serodiagnosis and Immunotherapy in Infectious Disease. 3: 307-316. DOI: 10.1016/0888-0786(89)90038-3 |
0.01 |
|
| 1989 |
Bauernfeind A, Przyklenk B, Horl G, Otto U, Schweighart S, Bornschein W. Significance of IgG-antibodies in sera of patients with gastritis, duodenitis and peptic ulcers Gastroduodenal Pathology and Campylobacter Pylori: Proceedings of the First Meeting of the European Campylobacter Pylori Study Group. Ics847. 205-206. |
0.01 |
|
| 1988 |
Bornschein W, Bauernfeind A, Heilmann K. Campylobacter pylori colonization of duodenal and gastric mucosa in duodenitis and duodenal ulcer Medizinische Klinik. 83: 585-589. PMID 3185416 |
0.01 |
|
| 1988 |
Przyklenk B, Bauernfeind A. Significance of immunologic factors in cystic fibrosis Scandinavian Journal of Gastroenterology. 23: 103-109. DOI: 10.3109/00365528809090227 |
0.01 |
|
| 1988 |
Przyklenk B, Bauernfeind A, Bertele RM, Deinhardt F, Harms K. Viral infections of the respiratory tract in patients with cystic fibrosis Serodiagnosis and Immunotherapy in Infectious Disease. 2: 217-225. DOI: 10.1016/0888-0786(88)90057-1 |
0.01 |
|
| 1987 |
Przyklenk B, Bauernfeind A, Hörl G, Emminger G. Serologic response to candida albicans and aspergillus fumigatus in cystic fibrosis Infection. 15: 308-310. PMID 3312024 DOI: 10.1007/BF01644143 |
0.01 |
|
| 1987 |
Bauernfeind A, Hörl G. Novel R-factor borne β-lactamase of Escherichia coli confering resistance to cephalosporins Infection. 15: 257-259. PMID 3312022 DOI: 10.1007/BF01644127 |
0.01 |
|
| 1987 |
Bauernfeind A, Emminger G, Hörl G, Lorbeer B, Przyklenk B, Weisslein-Pfister C. Selective pressure of antistaphylococcal chemotherapeutics in favour of pseudomonas aeruginosa in cystic fibrosis Infection. 15: 469-470. PMID 3125114 DOI: 10.1007/BF01647240 |
0.01 |
|
| 1987 |
Bauernfeind A, Emminger G, Hörl G, Ott S, Przyklenk B, Weisslein-Pfister C. Bacteriological effects of anti-pseudomonas aeruginosa chemotherapy in cystic fibrosis Infection. 15: 403-406. PMID 3121519 DOI: 10.1007/BF01647753 |
0.01 |
|
| 1986 |
Bauernfeind A, Hörl G. Imipenem resistance in Pseudomonas aeruginosa | Imipenem-Resistenz bei Pseudomonas aeruginosa Immunitat Und Infektion. 14: 221-224. PMID 3100425 |
0.01 |
|
| Hide low-probability matches. |